Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by WarrantOfficeron Sep 05, 2024 12:37pm
127 Views
Post# 36210095

Management

Management Formulation work for the five remaining products is complete a year after the PR on 14 Spet 2023 stating customers wanted a full line of products.....I know the pace in medical development can be slow. Clinical trials another two months to complete, it will take longer. 

The order page on the website gives you the impression that the entire product line is currently avavilable, when in fact it cannot be, as stated by todays PR. I phoned the 1-877-398-6866 order number,  a prerecorded message is played that does not even pronounce the name of the company properly or coherently. There is no-one to answer the call, it goes to a voice mail box, which makes sense as it seems there is currently zero products for sale. Why have the illlusion of products for sale?

Back to the prerecorded message stating the companies name in an unrecognizable manner, IMO indicates, and I keep sharing this time and time again,  management needs a shake up. 
<< Previous
Bullboard Posts
Next >>